Developing Immuno-STAT Biologics for the treatment of cancer, chronic infectious diseases and autoimmune diseases.
The”Cue Biopharma platform”was developed out of the laboratory of Steven Almo, Ph.D., Chair of the Department of Biochemistry at Albert Einstein College of Medicine/Montefiore Medical Center. Dr. Almo,”with co-founders and senior scientific advisors Ron Seidel III, Ph.D., and Rudy Chaparro,”pioneered the work that led to Cue Biopharma’s Immuno-STAT platform as part of a five-year, Specialized Center grant from the National Institutes of Health (NIH). This funding enabled the technology to be built into an industry-scale drug design platform capable of rapid and efficient molecular prototyping and development. Cue Biopharma is leveraging these design capabilities in its discovery efforts.
About Cue Biopharma
Cue Biopharma (NASDAQ: CUE), a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T”cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Cue Biopharma’s off-the-shelf biologics are designed to modulate the activity of a patient’s immune system utilizing a modular, rationally engineered therapeutic framework that mimics nature’s own signals, or “cues,” in selectively stimulating or inhibiting disease-relevant T cells for cancers and infections or autoimmune diseases, respectively. In this way, Cue Biopharma’s biologics avoid the systemic and indiscriminate immune activation (in cancer or infectious disease) or broad immunosuppression (in autoimmune diseases) of available immune-modulating drugs that can lead to deleterious effect, adverse events, dose-limiting toxicities, treatment discontinuation, and inadequate efficacy.
Headquartered in Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.
Up next – Provention Bio
Intercepting and preventing immune-related diseases
Provention Bio (NASDAQ: PRVB), is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threating immune-mediated diseases.